한글목차

세계 자연살해(NK) 세포 치료 시장 규모는 2024년 32억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 시장 규모가 86억 달러에 달해 2025년부터 2033년까지 11.8%의 연평균 성장률(CAGR)을 기록할 것으로 예측했습니다. 고령 인구의 증가와 함께 암 신흥국 시장의 개발 위험이 증가하면서 시장을 견인하고 있습니다.

자연살해(NK) 세포 치료 시장 동향:

병용요법의 인기 상승

치료 효과를 높이기 위해 NK세포 치료와 다른 치료법을 병행하는 것이 널리 보급되고 있습니다. 예를 들어, Innate Pharma의 항 CD22 면역독소인 Lumoxiti는 모세포백혈병에서 CD22를 발현하는 암세포를 파괴하고 표적으로 삼기 위해 NK세포와 병용하여 사용하고 있습니다. 또한, 이 접근법은 두 가지 치료법의 장점을 모두 활용합니다. 이 외에도 2024년 5월에는 자가면역질환, 암, 감염질환에 대한 혁신적인 세포 치료 플랫폼을 개발하는 바이오 제약기업인 Coeptis Therapeutics Holdings, Inc.가 여러 항원을 표적으로 하는 SNAP-CAR NK세포를 발표했습니다.

높아지는 규제 당국의 승인

NK 세포 제조의 신뢰성과 효율성 향상에 대한 정부기관의 관심 증가는 중요한 성장 촉진요인으로 작용하고 있습니다. 또한, 정부 기관은 실험실 연구를 실행 가능한 임상 치료로 전환하도록 장려하고 있으며, 이는 당분간 시장을 계속 활성화시킬 것으로 보입니다. 예를 들어, 2024년 4월 차세대 NK세포 치료 혁신 선도기업인 인제니움 테라퓨틱스(Ingenium Therapeutics)는 미국 식품의약국(FDA)으로부터 급성 골수성 백혈병(AML) 치료제로 희귀질환 치료제 지정을 받았습니다.

실시간 모니터링에 대한 수요 증가

NK 세포 치료 개발에서 실시간 모니터링과 데이터 분석을 광범위하게 통합하여 치료 정확도와 환자 결과를 개선하고 있습니다. 또한, Bio-Techne의 Ella 시스템과 같은 플랫폼은 NK 세포가 증식하는 동안 사이토카인 생산을 정확하게 모니터링하여 세포의 최적의 기능을 보장할 수 있습니다. 또한, 실시간 분석을 통해 연구자는 배양 조건을 동적으로 조정할 수 있어 생산된 NK세포의 품질과 효능을 향상시킬 수 있습니다. 이는 시장에 긍정적인 영향을 미치고 있습니다.

목차

제1장 서문

제2장 조사 범위와 조사 방법

• 조사 목적
• 이해관계자
• 데이터 소스
  • 1차 정보
  • 2차 정보
• 시장 추정
  • 상향식 접근
  • 하향식 접근
• 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 자연살해(NK) 세포 치료 시장

• 시장 개요
• 시장 실적
• COVID-19의 영향
• 시장 예측

제6장 시장 내역 : 요법별

• NK 세포 치료
• NK 세포를 표적으로 한 항체

제7장 시장 내역 : 용도별

• 암
• 소화기질환
• 면역 증식성 질환
• 기타

제8장 시장 내역 : 최종사용자별

• 병원
• 연구 센터·기관
• 기타

제9장 시장 내역 : 지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 인도네시아
  • 기타
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 러시아
  • 기타
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카

제10장 SWOT 분석

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

제13장 가격 분석

제14장 경쟁 구도

• 시장 구조
• 주요 기업
• 주요 기업 개요
  • Affimed GmbH
  • Bristol-Myers Squibb Company
  • Fate Therapeutics
  • Fortress Biotech Inc.
  • Glycostem Therapeutics
  • Innate Pharma S.A.
  • Kuur Therapeutics Inc.(Athenex Inc.)
  • Nkarta Inc.
  • Takeda Pharmaceutical Company Limited
  • Ziopharm Oncology Inc.

영문목차

The global natural killer cells therapeutics market size reached USD 3.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.6 Billion by 2033, exhibiting a growth rate (CAGR) of 11.8% during 2025-2033. The rising risks of developing cancer, along with the expanding geriatric population, are propelling the market.

Natural Killer Cells Therapeutics Market Trends:

Increasing Popularity of Combination Therapies

Combining NK cell therapies with other treatment modalities to enhance therapeutic efficacy is gaining extensive traction. For example, Innate Pharma's Lumoxiti, an anti-CD22 immunotoxin, is adopted in conjunction with NK cells to destroy and target CD22-expressing cancer cells in hairy cell leukemia. Moreover, this approach leverages the strengths of both therapies. Besides this, in May 2024, Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.

Growing Regulatory Approval

The rising focus among government agencies on enhancing the reliability and efficiency of NK cell production is acting as a significant growth-inducing factor. Furthermore, they are encouraging the translation of laboratory research into viable clinical therapies, which will continue to fuel the market over the foreseeable future. For example, in April 2024, Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

Rising Demand for Real-Time Monitoring

The widespread integration of real-time monitoring and data analytics into NK cell therapy development is enhancing treatment precision and patient outcomes. Moreover, platforms like Bio-Techne's Ella system enable precise monitoring of cytokine production during NK cell expansion, thereby ensuring optimal cell functionality. Real-time analytics also allow researchers to adjust culture conditions dynamically, which aids in improving the quality and effectiveness of the NK cells produced. This is positively influencing the market.

Global Natural Killer Cells Therapeutics Industry Segmentation:

Breakup by Therapeutics:

• NK Cell Therapies
• NK Cell Directed Antibodies

Currently, NK cell directed antibodies hold the majority of the total market share

NK cell directed antibodies target natural killer cells to enhance their ability to recognize and destroy cancer cells. For example, Affimed's AFM13, a bispecific NK cell engager, targets CD30 on cancer cells and CD16A on NK cells.

Breakup by Application:

• Cancer
• Gastrointestinal Diseases
• Immunoproliferative Disorders
• Others

Cancer currently exhibits a clear dominance in the market

The inflating need for effective cancer treatments drives the segment's growth. Recent product launches have underscored the potential of NK cell-based therapies in oncology. For instance, Fate Therapeutics' FT596 is an off-the-shelf, iPSC-derived NK cell therapy designed to target multiple cancer types, including B-cell malignancies.

Breakup by End User:

• Hospitals
• Research Centers and Institutes
• Others

Currently, research centers and institutes hold the majority of the total market share

Research centers and institutes offer high-quality reagents and technologies that streamline NK cell research, which is increasing the natural killer cells therapeutics market share. For example, Bio-Techne's Cloudz Human NK Cell Expansion Kit allows researchers to expand NK cells ex vivo efficiently.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

Advancements in biotechnology and a strong focus on innovative cancer treatments are primarily catalyzing the market in North America. According to the IMARC, the United States cancer immunotherapy market size is projected to exhibit a growth rate (CAGR) of 10.90% during 2024-2032. Besides this, collaborations between biotech firms are strengthening the regional market.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Affimed GmbH
• Bristol-Myers Squibb Company
• Fate Therapeutics
• Fortress Biotech Inc.
• Glycostem Therapeutics
• Innate Pharma S.A.
• Kuur Therapeutics Inc. (Athenex Inc.)
• Nkarta Inc.
• Takeda Pharmaceutical Company Limited
• Ziopharm Oncology Inc.

Key Questions Answered in This Report

• 1.What was the size of the global natural killer cells therapeutics market in 2024?
• 2.What is the expected growth rate of the global natural killer cells therapeutics market during 2025-2033?
• 3.What are the key factors driving the global natural killer cells therapeutics market?
• 4.What has been the impact of COVID-19 on the global natural killer cells therapeutics market?
• 5.What is the breakup of the global natural killer cells therapeutics market based on the therapeutics?
• 6.What is the breakup of the global natural killer cells therapeutics market based on the application?
• 7.What is the breakup of the global natural killer cells therapeutics market based on the end user?
• 8.What are the key regions in the global natural killer cells therapeutics market?
• 9.Who are the key players/companies in the global natural killer cells therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Natural Killer Cells Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapeutics

• 6.1 NK Cell Therapies
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 NK Cell Directed Antibodies
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Application

• 7.1 Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Gastrointestinal Diseases
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Immunoproliferative Disorders
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Research Centers and Institutes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Affimed GmbH
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Bristol-Myers Squibb Company
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Fate Therapeutics
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Fortress Biotech Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Glycostem Therapeutics
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Innate Pharma S.A.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Kuur Therapeutics Inc. (Athenex Inc.)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Nkarta Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Takeda Pharmaceutical Company Limited
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Ziopharm Oncology Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials